LivaNova (NASDAQ:LIVN - Get Free Report) was downgraded by stock analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a report released on Wednesday.
LIVN has been the subject of a number of other reports. Stifel Nicolaus dropped their price objective on LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday. Robert W. Baird lifted their target price on LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. Mizuho reduced their price target on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research report on Wednesday. Wolfe Research cut shares of LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday. Finally, Needham & Company LLC reduced their target price on shares of LivaNova from $75.00 to $64.00 and set a "buy" rating on the stock in a report on Wednesday. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, LivaNova currently has an average rating of "Buy" and a consensus target price of $64.20.
Check Out Our Latest Research Report on LIVN
LivaNova Trading Up 1.7 %
Shares of LIVN stock traded up $0.70 during trading hours on Wednesday, hitting $41.63. The company had a trading volume of 807,916 shares, compared to its average volume of 582,675. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The stock has a market capitalization of $2.26 billion, a PE ratio of 99.12 and a beta of 1.00. The company's fifty day moving average is $47.40 and its 200 day moving average is $49.53. LivaNova has a fifty-two week low of $40.37 and a fifty-two week high of $64.47.
Insider Transactions at LivaNova
In other news, Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares of the company's stock, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.27% of the company's stock.
Institutional Trading of LivaNova
A number of hedge funds and other institutional investors have recently bought and sold shares of LIVN. State of Alaska Department of Revenue increased its holdings in shares of LivaNova by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company's stock valued at $328,000 after acquiring an additional 425 shares during the last quarter. abrdn plc boosted its holdings in LivaNova by 43.8% in the third quarter. abrdn plc now owns 232,025 shares of the company's stock valued at $12,191,000 after purchasing an additional 70,618 shares in the last quarter. Emerald Advisers LLC increased its stake in LivaNova by 2.1% in the third quarter. Emerald Advisers LLC now owns 695,505 shares of the company's stock valued at $36,542,000 after purchasing an additional 14,302 shares during the last quarter. Atria Investments Inc raised its holdings in LivaNova by 6.2% during the third quarter. Atria Investments Inc now owns 5,653 shares of the company's stock worth $297,000 after purchasing an additional 331 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D raised its holdings in LivaNova by 38.3% during the third quarter. State of New Jersey Common Pension Fund D now owns 42,539 shares of the company's stock worth $2,235,000 after purchasing an additional 11,782 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.
About LivaNova
(
Get Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Featured Articles
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
